Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

CUSIP: 45719W205

Q4 2025 13F Holders as of 31 Dec 2025

Holder snapshot 6 signals
Share change
+35,184,865
SEC-reported price per share
$2.05
Number of holders
73
Value change
+$72,128,708
Number of buys
42
Number of sells
15
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
135,127,605

Security key

45719W205

Report period

Q4 2025

Institutions

73

Top holders

10

Ownership snapshot

Top reported holders of IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Fairmount Funds Managemen...
Disclosed value leader
Fairmount Funds Managemen...
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G 13F 3/4/5 Lead comparable stake: 9.9% 13D/G row: Fairmount Funds Management LLC Showing 1-6 of 15 holder rows.

Quick read

Fairmount Funds Management LLC leads the comparable SEC ownership view at 9.9%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Fairmount Funds Management LLC's linked filing trail.
Comparable ownership Top 5
Fairmount Funds Management LLC 9.9%
ARMISTICE CAPITAL, LLC 5%
Sands Capital Life Sciences Pulse... 9.6%
Sands Capital Alternatives, LLC 8.1%
Soleus Capital Management, L.P. 4.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Fairmount Funds Management LLC
13D/G 13F
Company
9.9%
$24,922,202
12,461,101 shares
+$10,885,052 31 Dec 2025
ARMISTICE CAPITAL, LLC
13D/G
5%
$7,975,554
3,529,006 shares
$0 31 Dec 2024
Sands Capital Life Sciences Pulse Fund II, L.P.
3/4/5
10%+ Owner
9.6%
$18,877,499
13,018,965 shares
+$2,999,999 21 Nov 2025
Sands Capital Alternatives, LLC
13F
Company
13F
8.1%
$17,739,000
10,950,000 shares
30 Sep 2025
Soleus Capital Management, L.P.
13F
Company
13F
4.7%
$10,246,500
6,325,000 shares
30 Sep 2025
PERCEPTIVE ADVISORS LLC
13F
Company
13F
4%
$8,782,940
5,421,568 shares
30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
73
Shares
106,415,262
Rows available
73
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
53
Q4 2025 holders
73
Holder diff
20
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .